Author: Sandra De Meyer; Denisa Bojkova; Jindrich Cinati; Ellen Van Damme; Christophe Buyck; Marnix Van Loock; Brian Woodfall; Sandra Ciesek
Title: Lack of Antiviral Activity of Darunavir against SARS-CoV-2 Document date: 2020_4_8
ID: 679qfp2s_30
Snippet: Current data on the therapeutic effect of HIV protease inhibitors in patients with COVID-19 are far from comprehensive. This study demonstrated that DRV showed no in vitro antiviral activity against SARS-CoV-2 at clinically relevant concentrations. Furthermore, structural analyses using protease structures are consistent with these data. DRV binds to the active site of the HIV virus' dimeric aspartic protease (14) . The crystal structure of this .....
Document: Current data on the therapeutic effect of HIV protease inhibitors in patients with COVID-19 are far from comprehensive. This study demonstrated that DRV showed no in vitro antiviral activity against SARS-CoV-2 at clinically relevant concentrations. Furthermore, structural analyses using protease structures are consistent with these data. DRV binds to the active site of the HIV virus' dimeric aspartic protease (14) . The crystal structure of this protease is well-elucidated and has been shown to have an extensive hydrogen-bonding network with DRV, allowing for the potent in vitro activity (EC 50 values = 1.2 to 8.5 nM) of this protease inhibitor against HIV (6-7).
Search related documents:
Co phrase search for related documents- active site and crystal structure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active site and HIV protease inhibitor: 1, 2, 3, 4, 5
- active site and HIV virus: 1, 2, 3, 4, 5, 6, 7
- active site and hydrogen bonding: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active site and hydrogen bonding network: 1
- active site and protease crystal structure: 1, 2, 3, 4, 5
- active site and protease inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active site and protease structure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral activity and crystal structure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral activity and HIV protease inhibitor: 1, 2, 3, 4, 5, 6, 7
- antiviral activity and HIV virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral activity and hydrogen bonding: 1, 2, 3, 4, 5, 6, 7
- antiviral activity and protease crystal structure: 1, 2, 3, 4, 5
- antiviral activity and protease inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral activity and protease structure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- aspartic protease and HIV protease inhibitor: 1
- aspartic protease and protease inhibitor: 1, 2, 3
- clinically relevant concentration and HIV virus: 1
- crystal structure and HIV virus: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date